Novartis Escapes Some Lotensin Claims

Law360, New York (March 25, 2008, 12:00 AM EDT) -- A federal district judge has tossed some of the claims brought against Novartis Pharmaceuticals Corp. by a woman who alleges that her infant son died due to complications from the popular hypertension drug Lotensin, which she took during the first trimester of her pregnancy.

On Tuesday, U.S. District Judge Martin Reidinger partially granted Novartis' motion to dismiss, ruling that the failure to warn and inadequate labeling charges were preempted by the Food and Drug Administration labeling process.

The origins of the suit date back several years,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.